Atlas Trials

Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study

Clinical trial NCT07206511 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07206511
Sponsor
Shanghai Zhongshan Hospital
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Unresectable Hepatocellular Carcinom
Start date
2025-10-09
Primary completion
2028-06-30
Enrollment
278

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.